Understanding Your Child's Genetic and MRI Reports
At a Glance
A confirmed SPAX8 diagnosis requires pathogenic or likely pathogenic variants in both copies of NKX6-2, interpreted alongside the child's clinical findings. MRI may show hypomyelination or cerebellar changes, but results vary and repeat scans are individualized.
Navigating the technical language of medical reports can be daunting. For NKX6-2-related leukodystrophy (SPAX8), the diagnosis is built using two main pieces of evidence: your child’s genetic “blueprint” and the “roadmap” of their brain provided by an MRI. Understanding these reports allows you to partner more effectively with your child’s medical team.
The Genetic Report: Confirming the Cause
To confirm a diagnosis of SPAX8, genetic testing—often through Exome Sequencing or a specialized Leukodystrophy Panel—must find changes in both copies of the NKX6-2 gene [1][2].
Autosomal Recessive Inheritance
This condition is autosomal recessive. We all have two copies of the NKX6-2 gene (one from each parent). In this condition, both copies must have a pathogenic variant for symptoms to occur [1]. Parents are typically “carriers,” meaning they have one working copy and one non-working copy, and they do not show any symptoms themselves [1].
What to Look for on the Report
A complete and definitive genetic report should include these specific details:
- Biallelic Variants: The report must show that both alleles of the gene are affected.
- Zygosity: This indicates the arrangement of the variant. It may be listed as homozygous (the exact same variant on both copies; the report may only list one unique variant while showing it is present on both alleles) or compound heterozygous (two different variants in the same gene) [1][3].
- Variant Nomenclature: Look for a string of letters and numbers like c.589C>T or p.Arg197Cys. These identify the exact location and type of change in the DNA [4].
- Pathogenicity Classification: The lab should classify the variant as Pathogenic or Likely Pathogenic. A “Variant of Uncertain Significance” (VUS) means the lab isn’t sure yet if the change causes disease. A VUS is explicitly insufficient to confirm or exclude a diagnosis and should not be a basis for changing management on its own [5][6].
The MRI Report: Seeing the Impact
An MRI provides a picture of how the NKX6-2 changes are affecting the brain. While the genetic test tells us why the condition is happening, the MRI shows us what is happening.
Key Imaging Features
- Hypomyelination: This is the signature of SPAX8. On an MRI, it appears as a widespread lack of the normal “white matter” signal that represents myelin insulation [2][1].
- Cerebellar Involvement: The report may mention cerebellar atrophy (shrinking of the balance center) or unusual signals in the cerebellar white matter [7][8].
- Variable Presentation: It is crucial to know that imaging can vary. Some children with the milder form may show cerebellar atrophy with very little evidence of myelin loss [8]. Conversely, some children may have severe symptoms before the MRI shows clear hypomyelination [1].
Crucial Note on Serial MRIs: In cases where early imaging is inconclusive, clinicians may use serial MRIs (for example, at least six months apart) as an expert-guided option to distinguish delayed myelination from true hypomyelination [9][10]. However, this is not a mandatory lifelong surveillance schedule. If a molecular diagnosis is already confirmed, serial MRI might not be necessary, and timing is individualized based on clinical need and the risks of sedation.
Completeness Checklist for Parents
When you review your child’s genetic report, ensure these elements are present to discuss with your genetic counselor:
- Gene Name: Is NKX6-2 clearly identified?
- Affected Alleles: Does the report demonstrate two affected alleles (biallelic)? [1]
- Classification: Are the variants classified as “Pathogenic” or “Likely Pathogenic” under current laboratory standards? [5]
- Phase: If compound heterozygous, has phase been established (are they in trans, meaning on opposite copies)? This usually requires parental testing. [3]
- Clinical Correlation: Do the genetics team and clinician agree these genetic findings fit the clinical picture? [5]
By verifying these details, you ensure that your child’s diagnosis is grounded in the most accurate and up-to-date genetic science.
Common questions in this guide
What does it mean if my child has two disease-causing NKX6-2 variants?
What is the difference between homozygous and compound heterozygous results?
What MRI findings can occur with SPAX8?
Does my child need repeat MRI scans after a molecular diagnosis?
What should happen if genetic testing finds only one NKX6-2 variant?
Can parents carry NKX6-2 variants without having symptoms?
Get notified when new evidence is published on NKX6-2-related autosomal recessive hypomyelinating leukodystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
Genetic and phenotypic characterization of NKX6-2-related spastic ataxia and hypomyelination.
Chelban V, Alsagob M, Kloth K, et al.
European journal of neurology 2020; (27(2)):334-342 doi:10.1111/ene.14082.
PMID: 31509304 - 2
Biallelic mutations in the homeodomain of NKX6-2 underlie a severe hypomyelinating leukodystrophy.
Dorboz I, Aiello C, Simons C, et al.
Brain : a journal of neurology 2017; (140(10)):2550-2556 doi:10.1093/brain/awx207.
PMID: 28969374 - 3
Expanding the clinical and genetic spectra of NKX6-2-related disorder.
Baldi C, Bertoli-Avella AM, Al-Sannaa N, et al.
Clinical genetics 2018; (93(5)):1087-1092 doi:10.1111/cge.13221.
PMID: 29388673 - 4
HGVS Recommendations for the Description of Sequence Variants: 2016 Update.
den Dunnen JT, Dalgleish R, Maglott DR, et al.
Human mutation 2016; (37(6)):564-9 doi:10.1002/humu.22981.
PMID: 26931183 - 5
Clinical Interpretation of Sequence Variants.
Zhang J, Yao Y, He H, Shen J
Current protocols in human genetics 2020; (106(1)):e98 doi:10.1002/cphg.98.
PMID: 32176464 - 6
Efficacy of Exome-Targeted Capture Sequencing to Detect Mutations in Known Cerebellar Ataxia Genes.
Coutelier M, Hammer MB, Stevanin G, et al.
JAMA neurology 2018; (75(5)):591-599 doi:10.1001/jamaneurol.2017.5121.
PMID: 29482223 - 7
Expanding the clinical and neuroimaging features of NKX6-2-related hereditary spastic ataxia type 8.
Hosseini Bereshneh A, Hosseipour S, Rasoulinezhad MS, et al.
European journal of medical genetics 2020; (63(5)):103868 doi:10.1016/j.ejmg.2020.103868.
PMID: 32004679 - 8
Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination.
Chelban V, Patel N, Vandrovcova J, et al.
American journal of human genetics 2017; (100(6)):969-977 doi:10.1016/j.ajhg.2017.05.009.
PMID: 28575651 - 9
Rare forms of hypomyelination and delayed myelination.
Mura E, Parazzini C, Tonduti D
Handbook of clinical neurology 2024; (204()):225-252 doi:10.1016/B978-0-323-99209-1.00002-8.
PMID: 39322381 - 10
Hypomyelinating disorders: An MRI approach.
Barkovich AJ, Deon S
Neurobiology of disease 2016; (87()):50-8.
PMID: 26477299
This page is for informational purposes and does not constitute medical advice about your child's SPAX8 reports. Your child's genetics, neurology, and radiology teams should interpret the findings and guide testing or MRI decisions.